2型糖尿病合并慢性肾脏病患者多重用药安全中国专家共识  

Chinese Expert Consensus on Medication Safety in Polypharmacy in Type 2 Diabetics with Chronic Kidney Disease

作　　者：中华医学会临床药学分会 徐阿晶[2] 张健[2] Chinese Medical Association Clinical Pharmacy Branch;XU Ajing;ZHANG Jian

机构地区：[1]不详 [2]上海交通大学医学院附属新华医院

出　　处：《中国全科医学》2022年第23期2819-2835,共17页Chinese General Practice

基　　金：国家重点研发计划“主动健康和老龄化科技应对”重点专项——老年常见病多重用药风险管控体系的研究和应用示范项目(2020YFC2005500);老年常见病多重用药安全指南知识图谱及高风险药物管理研究(2020YFC2005502)。

摘　　要：糖尿病已成为一个严重的全球公共卫生问题,随着2型糖尿病(T2DM)患病率的增加,T2DM合并慢性肾脏病(CKD)发病率也呈上升趋势。目前国内外未见较为全面的T2DM合并CKD患者的临床多重用药安全指南。本共识旨在针对T2DM合并CKD患者临床多重用药安全问题,为中国的临床药师与患者提供相关指导意见,并汇总用法用量、相关药学特点、特殊人群用药等信息,服务于临床医护人员规范化用药需求。Diabetes is a serious public health problem worldwide.The prevalence of chronic kidney disease(CKD)secondary to type 2 diabetes mellitus(T2DM)is growing with the increase of T2DM prevalence.There is no comprehensive guideline on medication safety in polypharmacy in patients with T2DM-related CKD.This consensus provides guidance on safety issues in polypharmacy for clinical pharmacists and Chinese patients with T2DM-related CKD,and a summary of the information on usage and dosage,and related pharmaceutical characteristics of drugs as well as medication for special populations for supporting clinical medical workers in delivering standardized medication services.

关 键 词：糖尿病 2型 慢性肾脏病 肾功能不全 慢性 多重用药 专家共识 指南 

分 类 号：R587.1[医药卫生—内分泌] R692[医药卫生—内科学]